{"id":50771,"date":"2023-09-20T09:12:58","date_gmt":"2023-09-20T09:12:58","guid":{"rendered":"https:\/\/medsname.com\/trajenta\/"},"modified":"2026-05-01T10:49:11","modified_gmt":"2026-05-01T10:49:11","slug":"trajenta","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/trajenta\/","title":{"rendered":"Trajenta"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 R\u0103spuns rapid \u2014 Ce este Trajenta?<\/h3>\n<p style=\"margin:0;\"><strong>Trajenta<\/strong> este o marc\u0103 a <strong>linagliptin<\/strong> (5 mg), o <strong>inhibitor DPP-4<\/strong> (inhibitor al dipeptidil peptidazei-4, numit \u0219i \u201cgliptin\u0103\u201d) utilizat pentru <strong>diabetului de tip 2<\/strong>. Ac\u021bioneaz\u0103 prin blocarea enzimei DPP-4, care \u00een mod normal descompune hormonii incretini (GLP-1 \u0219i GIP). Niveluri mai ridicate de incretin\u0103 stimuleaz\u0103 eliberarea de insulin\u0103 \u0219i suprima glucagonul <strong>doar c\u00e2nd nivelul glucozei din s\u00e2nge este ridicat<\/strong> \u2014 astfel, inhibitorii DPP-4 produc un efect dependent de glucoz\u0103 \u0219i <strong>nu provoac\u0103 hipoglicemie<\/strong> ca monoterapie. Reducere HbA1c: 0,6\u20130,8 puncte. Neutru din punct de vedere al greut\u0103\u021bii. Dozare o dat\u0103 pe zi (majoritatea gliptinelor). Singurul DPP-4 care nu <strong>prime\u0219te,<\/strong> necesit\u0103 ajustarea dozei \u00een insuficien\u021ba renal\u0103 \u2014 o tablet\u0103, o doz\u0103, indiferent de func\u021bia renal\u0103. Neutru din punct de vedere cardiovascular \u00een studiile de rezultat CARMELINA \u0219i CAROLINA. Doz\u0103: 5 mg o dat\u0103 pe zi \u2014 o doz\u0103 fix\u0103 indiferent de func\u021bia renal\u0103 sau hepatic\u0103. Efectele secundare principale sunt u\u0219oare \u2014 simptome respiratorii superioare, cefalee, pancreatit\u0103 rar\u0103. Evita\u021bi \u00een diabetul de tip 1 \u0219i CAD.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n<h2 class=\"wp-block-heading\">Ce este Trajenta?<\/h2>\n<p>Trajenta este un medicament antidiabetic oral care con\u021bine <strong>linagliptin<\/strong> (5 mg), fabricat de Boehringer Ingelheim. Disponibil \u00een cutii de 30, 60, 90 sau 180 de comprimate. Este prescris pentru adul\u021bii cu diabet zaharat de tip 2, de obicei \u00een asociere cu metformin\u0103 sau ca tratament de linia a doua sau a treia.<\/p>\n<p>linagliptina apar\u021bine clasei inhibitorilor DPP-4 (\u201cgliptine\u201d) \u2014 aprobat\u0103 pentru prima dat\u0103 \u00een 2011 (marca original\u0103: Trajenta, Boehringer Ingelheim \/ Eli Lilly). Gliptinele sunt utilizate pe scar\u0103 larg\u0103 deoarece nu afecteaz\u0103 greutatea corporal\u0103, prezint\u0103 un risc sc\u0103zut de hipoglicemie \u0219i pot fi utilizate la pacien\u021bii cu afec\u021biuni renale, cu ajustarea corespunz\u0103toare a dozei.<\/p>\n<h2 class=\"wp-block-heading\">Cum func\u021bioneaz\u0103 Trajenta?<\/h2>\n<p>Dup\u0103 mese, intestinul elibereaz\u0103 doi hormoni incretini \u2014 <strong>GLP-1 (peptid-1 asem\u0103n\u0103tor glucagonului)<\/strong> \u0219i <strong>GIP (peptid insulinotropic dependent de glucoz\u0103)<\/strong>. Ace\u0219ti hormoni stimuleaz\u0103 pancreasul s\u0103 elibereze insulin\u0103 \u0219i ficatul s\u0103 inhibe glucagonul, dar sunt rapid descompu\u0219i de enzima <strong>dipeptidil peptidaza-4 (DPP-4)<\/strong> \u00een c\u00e2teva minute.<\/p>\n<p>linagliptina blocheaz\u0103 DPP-4. Acest lucru cre\u0219te nivelul activ al GLP-1 \u0219i GIP, produc\u00e2nd:<\/p>\n<ul>\n<li><strong>Eliberarea de insulin\u0103 dependent\u0103 de glucoz\u0103<\/strong> din celulele beta pancreatice \u2014 doar c\u00e2nd glicemia este crescut\u0103<\/li>\n<li><strong>Suprimarea glucagonului<\/strong> din celulele alfa, reduc\u00e2nd produc\u021bia hepatic\u0103 de glucoz\u0103 dup\u0103 mese<\/li>\n<li>\u00cencetinire moderat\u0103 a golirii gastrice<\/li>\n<\/ul>\n<p>Deoarece eliberarea de insulin\u0103 este <em>dependent\u0103 de glucoz\u0103<\/em>, inhibitorii DPP-4 nu provoac\u0103 hipoglicemie \u00een mod independent. Reducere tipic\u0103 a HbA1c: <strong>0,6\u20130,8 puncte procentuale<\/strong>. Efect asupra greut\u0103\u021bii: neutru. Efecte asupra tensiunii arteriale \u0219i lipidelor: neutre.<\/p>\n<h2 class=\"wp-block-heading\">Doza \u0219i administrare<\/h2>\n<p><strong>Doza standard:<\/strong> 5 mg o dat\u0103 pe zi \u2014 o doz\u0103 fix\u0103, indiferent de func\u021bia renal\u0103 sau hepatic\u0103. Trajenta poate fi luat\u0103 cu sau f\u0103r\u0103 alimente.<\/p>\n<ul>\n<li>Doza unic\u0103 zilnic\u0103 (de dou\u0103 ori pentru vildagliptin) \u2014 alege\u021bi un moment constant.<\/li>\n<li><strong>Timp de \u00eenjum\u0103t\u0103\u021bire \u0219i eliminare:<\/strong> &gt; 100 de ore (timp de \u00eenjum\u0103t\u0103\u021bire terminal lung); ~80% eliminat neschimbat prin cale biliar\u0103\/fecal\u0103 \u2014 doar aproximativ 5% renal.<\/li>\n<li><strong>Dozare renal\u0103:<\/strong> <strong>Nu este necesar\u0103 ajustarea dozei la orice valoare a eGFR<\/strong> \u2014 linagliptina este inhibitorul DPP-4 de preferin\u021b\u0103 pentru boala renal\u0103 cronic\u0103 (BRC), inclusiv pentru pacien\u021bii dializa\u021bi.<\/li>\n<li>Nu este necesar\u0103 ajustarea dozei hepatice pentru majoritatea gliptinelor (vildagliptin necesit\u0103 verificarea ALT ini\u021bial\u0103).<\/li>\n<li>Dac\u0103 rata\u021bi o doz\u0103 \u2014 omite\u021bi-o; lua\u021bi urm\u0103toarea la ora obi\u0219nuit\u0103. Nu dubla\u021bi doza.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Efecte Secundare<\/h2>\n<p>Inhibitorii DPP-4 sunt printre antidiabeticele orale cel mai bine tolerate. Majoritatea efectelor secundare sunt u\u0219oare \u0219i similare \u00een \u00eentreaga clas\u0103.<\/p>\n<p><strong>Frecvente:<\/strong><\/p>\n<ul>\n<li>Infec\u021bie a tractului respirator superior, nazofaringit\u0103<\/li>\n<li>Dureri de cap<\/li>\n<li>Tulbur\u0103ri gastrointestinale u\u0219oare \u2014 grea\u021b\u0103, diaree (mai pu\u021bin frecvente dec\u00e2t la metformin\u0103)<\/li>\n<\/ul>\n<p><strong>Pu\u021bin frecvente, dar importante:<\/strong><\/p>\n<ul>\n<li><strong>Pancreatit\u0103 acut\u0103<\/strong> \u2014 efect de clas\u0103 rar dar documentat; \u00eentrerupe\u021bi imediat dac\u0103 apar dureri abdominale severe<\/li>\n<li><strong>Dureri articulare severe (artralgie)<\/strong> \u2014 pot ap\u0103rea la s\u0103pt\u0103m\u00e2ni sau luni dup\u0103 ini\u021bierea tratamentului; de obicei se rezolv\u0103 la \u00eentrerupere<\/li>\n<li><strong>Hipersensibilitate\/angioedem<\/strong> \u2014 s-au raportat cazuri de pemfigoid bulos; \u00eentrerupe\u021bi tratamentul dac\u0103 apar leziuni cutanate cu vezicule<\/li>\n<li>Saxagliptin\u0103 specific: cre\u0219tere u\u0219oar\u0103 a riscului de spitalizare pentru insuficien\u021b\u0103 cardiac\u0103<\/li>\n<li>Sulfoniluree, insulin\u0103, meglitinide<\/li>\n<\/ul>\n<p>\u2014 efect hipoglicemiant aditiv. A\u0219tepta\u021bi-v\u0103 s\u0103 reduce\u021bi aceste doze atunci c\u00e2nd ad\u0103uga\u021bi un gliptin.<\/p>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<ul>\n<li><strong>Inhibitori puternici ai CYP3A4\/5<\/strong> \u2014 additive glucose-lowering. Expect to reduce these doses when adding a gliptin.<\/li>\n<li><strong>Strong CYP3A4\/5 inhibitors<\/strong> (ketoconazol, claritromicin\u0103, ritonavir, atazanavir) \u2014 cresc nivelurile de saxagliptin\u0103; reduce\u021bi doza de saxagliptin\u0103 la jum\u0103tate. Efect minim asupra sitagliptinei, linagliptinei, vildagliptinei.<\/li>\n<li><strong>Rifampicin\u0103<\/strong> \u2014 reduce moderat nivelurile de linagliptin\u0103; efectul poate avea relevan\u021b\u0103 clinic\u0103.<\/li>\n<li><strong>Inhibitori ACE<\/strong> \u2014 risc teoretic aditiv de angioedem; semnifica\u021bia clinic\u0103 este discutat\u0103.<\/li>\n<li><strong>Digoxin\u0103<\/strong> \u2014 cre\u0219tere mic\u0103 a nivelului maxim cu sitagliptin\u0103; de obicei, f\u0103r\u0103 importan\u021b\u0103 clinic\u0103.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Cine nu ar trebui s\u0103 ia Trajenta?<\/h2>\n<ul>\n<li>Diabet zaharat de tip 1<\/li>\n<li>Cetoacidoz\u0103 diabetic\u0103<\/li>\n<li>Hipersensibilitate cunoscut\u0103 la linagliptin\u0103 sau alte inhibitori DPP-4<\/li>\n<li>Istoric de pancreatit\u0103 (relativ \u2014 discuta\u021bi alternative)<\/li>\n<li>Sarcin\u0103 \u0219i al\u0103ptare \u2014 date limitate; se prefer\u0103 alternative<\/li>\n<li>Saxagliptin\u0103 specific: insuficien\u021b\u0103 cardiac\u0103 sever\u0103<\/li>\n<li>Vildagliptin\u0103 specific: ALT sau AST &gt; de 3\u00d7 limita superioar\u0103 normal\u0103<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<p>P\u0103stra\u021bi Trajenta la temperaturi sub 30\u00b0C, \u00eentr-un loc uscat, \u00een blisterul original. Depozita\u021bi \u00eentr-un loc inaccesibil copiilor.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">Trajenta este acela\u0219i lucru cu linagliptina?<\/h3>\n<p>Da. Trajenta con\u021bine acela\u0219i ingredient activ ca \u0219i marca original\u0103. Autorit\u0103\u021bile de reglementare cer bioechivalen\u021b\u0103, a\u0219adar efectul clinic este acela\u0219i la aceea\u0219i doz\u0103.<\/p>\n<h3 class=\"wp-block-heading\">De ce s\u0103 alegi linagliptina \u00een loc de sitagliptin\u0103?<\/h3>\n<p>Principalul avantaj al linagliptinei este c\u0103 nu necesit\u0103 ajustarea dozei \u00een cazul bolilor renale \u2014 aceea\u0219i tablet\u0103 de 5 mg func\u021bioneaz\u0103 indiferent dac\u0103 eGFR este 90 sau 15. Sitagliptina are un set mai mare de date din studii de rezultat, dar necesit\u0103 reduceri de doz\u0103 cu 50% sau 75% \u00een cazul IRC moderate p\u00e2n\u0103 la severe. Pentru pacien\u021bii cu func\u021bie renal\u0103 stabil\u0103, cele dou\u0103 sunt similare din punct de vedere clinic.<\/p>\n<h3 class=\"wp-block-heading\">Trajenta poate cauza hipoglicemie?<\/h3>\n<p>Singur\u0103, nu. Inhibitorii DPP-4 ac\u021bioneaz\u0103 \u00eentr-un mod dependent de glucoz\u0103 \u2014 stimuleaz\u0103 eliberarea de insulin\u0103 doar atunci c\u00e2nd nivelul glucozei din s\u00e2nge este ridicat. Hipoglicemia devine o problem\u0103 doar atunci c\u00e2nd Trajenta este combinat\u0103 cu o sulfoniluree, meglitinid\u0103 sau insulin\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Trajenta poate cauza cre\u0219tere \u00een greutate?<\/h3>\n<p>Nu \u2014 inhibitorii DPP-4 sunt neutri din punct de vedere al greut\u0103\u021bii. Acesta este unul dintre motivele principale pentru care sunt prefera\u021bi \u00een locul sulfonilureelor la pacien\u021bii cu exces de greutate.<\/p>\n<h3 class=\"wp-block-heading\">Trajenta poate cauza pancreatit\u0103?<\/h3>\n<p>Pancreatita acut\u0103 este un efect de clas\u0103 rar, dar documentat. Riscul absolut este mic, iar studiile mari (TECOS, CARMELINA, SAVOR) nu au ar\u0103tat, \u00een general, un exces semnificativ din punct de vedere statistic. \u00centrerupe\u021bi imediat administrarea \u0219i consulta\u021bi un medic dac\u0103 apar dureri abdominale severe \u2014 mai ales dac\u0103 durerea se irradiaz\u0103 spre spate.<\/p>\n<h3 class=\"wp-block-heading\">C\u00e2t dureaz\u0103 p\u00e2n\u0103 \u00eencepe s\u0103 actioneze Trajenta?<\/h3>\n<p>Glicemia \u00een stare de repaus \u00eencepe s\u0103 scad\u0103 \u00een prima s\u0103pt\u0103m\u00e2n\u0103. Efectul maxim asupra HbA1c se observ\u0103 la 12 s\u0103pt\u0103m\u00e2ni. Dac\u0103 HbA1c nu a sc\u0103zut cu cel pu\u021bin 0,3\u20130,5% dup\u0103 3 luni, ar trebui luat\u0103 \u00een considerare o alt\u0103 terapie adjunctiv\u0103 (inhibitor SGLT-2 sau agonist GLP-1).<\/p>\n<h3 class=\"wp-block-heading\">Pot s\u0103 opresc brusc Trajenta dac\u0103 nu m\u0103 simt bine?<\/h3>\n<p>Da \u2014 inhibitorii DPP-4 pot fi \u00eentrerup\u021bi brusc f\u0103r\u0103 risc de hiperglicemie de rebond. Dac\u0103 dezvolta\u021bi dureri abdominale severe, b\u0103\u0219ici pe piele sau dureri articulare severe, opri\u021bi tratamentul \u0219i contacta\u021bi medicul.<\/p>\n<h3 class=\"wp-block-heading\">Unde pot cump\u0103ra Trajenta online?<\/h3>\n<p>Pute\u021bi comanda Trajenta (5 mg) de la MedsBase \u00een cutii de 30, 60, 90 sau 180 de comprimate. Livr\u0103m \u00een \u00eentreaga lume, cu ambalaj discret \u0219i stocuri originale certificate WHO-GMP.<\/p>\n<h2 class=\"wp-block-heading\">Medicamente \u00eenrudite pentru Diabet<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/januvia\/\">Januvia \u2014 Sitagliptin\u0103 25\/50\/100 mg (Merck)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/trajenta\/\">Trajenta \u2014 Linagliptin\u0103 5 mg (Boehringer Ingelheim)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/galvus\/\">Galvus \u2014 Vildagliptin\u0103 50 mg (Novartis)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/janumet\/\">Janumet \u2014 Combina\u021bie Sitagliptin + Metformin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/jardiance-empagliflozin\/\">Jardiance \u2014 Empagliflozin\u0103 (alternativ\u0103 SGLT-2)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/glycomet-sr\/\">Glycomet SR \u2014 Metformin cu eliberare prelungit\u0103<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/diabetes-medication\/\"><strong>Vizualiza\u021bi toate Medicamentele pentru Diabet<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 Dezaprobare medical\u0103.<\/strong> Aceast\u0103 pagin\u0103 are doar scop informativ \u0219i nu \u00eenlocuie\u0219te sfatul medical al unui profesionist calificat din domeniul s\u0103n\u0103t\u0103\u021bii. Inhibitorii DPP-4 sunt asocia\u021bi cu pancreatit\u0103 rar\u0103, dureri articulare severe \u0219i pemfigoid bulos \u2014 utiliza\u021bi \u00eentotdeauna sub \u00eendrumare medical\u0103 \u0219i opri\u021bi tratamentul cu evaluare prompt\u0103 dac\u0103 acestea apar.<\/div>","protected":false},"excerpt":{"rendered":"<h5>\u2705 Stimuleaz\u0103 secre\u021bia de insulin\u0103<br \/>\n\u2705 Sus\u021bine tratamentul diabetului<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te func\u021bia insulinic\u0103<br \/>\n\u2705 Op\u021biune de dozare o dat\u0103 pe zi<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te controlul glicemic<\/h5>\n<p><span style=\"color: #999999;\">Trajenta con\u021bine Linagliptin<\/span><\/p>","protected":false},"featured_media":50772,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3230,3231],"product_tag":[3278],"class_list":{"0":"post-50771","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-diabetes","9":"product_cat-diabetes-medication","10":"product_tag-linagliptin","12":"first","13":"outofstock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/50771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=50771"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/50772"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=50771"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=50771"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=50771"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=50771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}